CELC
Price
$53.07
Change
-$2.00 (-3.63%)
Updated
Sep 16 closing price
Capitalization
2.34B
61 days until earnings call
CLRB
Price
$5.13
Change
-$0.02 (-0.39%)
Updated
Sep 16 closing price
Capitalization
16.38M
Interact to see
Advertisement

CELC vs CLRB

Header iconCELC vs CLRB Comparison
Open Charts CELC vs CLRBBanner chart's image
Celcuity
Price$53.07
Change-$2.00 (-3.63%)
Volume$689.03K
Capitalization2.34B
Cellectar Biosciences
Price$5.13
Change-$0.02 (-0.39%)
Volume$18.82K
Capitalization16.38M
CELC vs CLRB Comparison Chart in %
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. CLRB commentary
Sep 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and CLRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 17, 2025
Stock price -- (CELC: $53.07 vs. CLRB: $5.13)
Brand notoriety: CELC and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 41% vs. CLRB: 15%
Market capitalization -- CELC: $2.34B vs. CLRB: $16.38M
CELC [@Biotechnology] is valued at $2.34B. CLRB’s [@Biotechnology] market capitalization is $16.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 1 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 1 green, 4 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 3 TA indicator(s) are bullish while CLRB’s TA Score has 4 bullish TA indicator(s).

  • CELC’s TA Score: 3 bullish, 5 bearish.
  • CLRB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CLRB is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а -12.67% price change this week, while CLRB (@Biotechnology) price change was -3.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.37%. For the same industry, the average monthly price growth was +6.95%, and the average quarterly price growth was +36.10%.

Reported Earning Dates

CELC is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+3.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($2.34B) has a higher market cap than CLRB($16.4M). CELC YTD gains are higher at: 305.424 vs. CLRB (-42.809). CLRB has higher annual earnings (EBITDA): -38.26M vs. CELC (-135.56M). CELC has more cash in the bank: 168M vs. CLRB (11M). CLRB has less debt than CELC: CLRB (454K) vs CELC (99.4M). CELC (0) and CLRB (0) have equivalent revenues.
CELCCLRBCELC / CLRB
Capitalization2.34B16.4M14,244%
EBITDA-135.56M-38.26M354%
Gain YTD305.424-42.809-713%
P/E RatioN/AN/A-
Revenue00-
Total Cash168M11M1,527%
Total Debt99.4M454K21,894%
FUNDAMENTALS RATINGS
CELC vs CLRB: Fundamental Ratings
CELC
CLRB
OUTLOOK RATING
1..100
7215
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
25100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3465
P/E GROWTH RATING
1..100
10071
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (56) in the Biotechnology industry is in the same range as CELC (86) in the Miscellaneous Commercial Services industry. This means that CLRB’s stock grew similarly to CELC’s over the last 12 months.

CELC's Profit vs Risk Rating (25) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew significantly faster than CLRB’s over the last 12 months.

CELC's SMR Rating (99) in the Miscellaneous Commercial Services industry is in the same range as CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's Price Growth Rating (34) in the Miscellaneous Commercial Services industry is in the same range as CLRB (65) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (71) in the Biotechnology industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that CLRB’s stock grew similarly to CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCCLRB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 28 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMTOX10.13N/A
N/A
AB All Market Real Return 1
FSBDX22.27N/A
N/A
Fidelity Series Blue Chip Growth
TEOOX10.48N/A
N/A
Transamerica Emerging Markets Eq R6
VKSCX18.95N/A
N/A
Virtus KAR Small-Mid Cap Core C
JLFSX12.44N/A
N/A
JHancock Global Climate Action I

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-3.63%
IMA - CELC
84%
Closely correlated
-4.97%
MRSN - CELC
62%
Loosely correlated
+0.56%
NEVPF - CELC
61%
Loosely correlated
N/A
SLXN - CELC
50%
Loosely correlated
-2.22%
ABOS - CELC
44%
Loosely correlated
-2.38%
More

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with QTTB. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
-0.39%
QTTB - CLRB
66%
Loosely correlated
+3.87%
ADCT - CLRB
42%
Loosely correlated
+3.44%
IBRX - CLRB
41%
Loosely correlated
+2.55%
ANAB - CLRB
39%
Loosely correlated
-3.77%
CELC - CLRB
37%
Loosely correlated
-3.63%
More